Statement: the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy.
Primary_evidence: INTERVENTION 1:    Five Days of Mammosite Therapy [Not Specified]
Secondary_evidence: INTERVENTION 1:    Bevacizumab Plus Paclitaxel   Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks INTERVENTION 2:    Bevacizumab Plus Capecitabine   Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks, Capecitabine 1000 mg/m² twice-daily, days 1-14, every 3 weeks